Characterization of Ti Alloys for Biomedical Applications.
Abstract not provided.
SEARCH · Search NASA
Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Abstract not provided.
Opioid overdoses killed more than 50,000 people in the U.S. in 2016, reaching epidemic proportions. New opioid drugs that suppress pain but are neither addictive nor likely to cause overdose deaths are now in the pharmaceutical pipeline, the result of decades of research into how medicines attach to and communicate with the body’s cells. Critical to that research was a new method of determining the structure of large biological molecules, using extremely powerful beams of X-rays developed and supported at shared research facilities by the Basic Energy Sciences (BES) office of DOE. Such X-ray studies are now central to new drug development: the BES facilities are used by the pharmaceutical industry to screen most new drug candidates.
Abstract not provided.
Abstract not provided.
Abstract not provided.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Engineered fullerenes (C{sub 60}) are extensively used for commercial and clinical applications based on their unique physicochemical properties. Such materials have also been recognized as byproducts of many industrial activities. Functionalization of C{sub 60} may significantly influence the nature of its interactions with biological systems, impacting its applications and raising uncertainties about its health effects. In the present study, we compared the bioimpact of two chemically modified fullerene derivatives, hexa carboxyl fullerene adduct (Hexa-C{sub 60}) and tris carboxyl fullerene adduct (tris-C{sub 60}) to pristine fullerene C{sub 60} encapsulated with gamma (gamma)-cyclodextrin C{sub 60} (CD-C{sub 60}), using human cutaneous epithelial cells (HEK) to simulate possible applications and occupational dermal exposure route. We report, for the first time, the discovery of premature senescence as a potential endpoint of nanomaterial elicited biological effects, providing a new paradigm for nanoparticle-induced toxicity in human cells. Moreover, this response appeared to be functionalization specific, in that, only tris-C{sub 60} induced senescence. We investigated key biological responses, such as cellular viability, intracellular ROS generation, cell proliferation and cell cycle responses. Our results indicate that the often observed 'anti-apoptotic' function of fullerene derivatives may be independent of their 'ROS scavenging' role as previously reported. We discovered that the tris-C{sub 60}-induced responses were associated with G{sub 0}/G{sub 1} cell cycle arrest and cellular senescence. On further evaluation of the molecular mechanisms underlying the senescent response, a significant decrease in the expression levels of HERC5 was noted. HERC5 is a ubiquitin ligase of the HERC family and is implicated to be involved in innate immune responses to viral and bacterial infections.
In the past decade, existing and new knowledge and datasets has been encoded in different ontologies for semantic web and biomedical research. The size of ontologies is often very large in terms of number of concepts and relationships, which makes the analysis of ontologies and the represented knowledge graph computational and time consuming. As the ontologies of various semantic web and biomedical applications usually show explicit hierarchical structures, it is interesting to explore the trade-offs between ontological scales and preservation/precision of results when we analyze ontologies. This paper presents the first effort of examining the capability of this idea via studying the relationship between scaling biomedical ontologies at different levels and the semantic similarity values. We evaluate the semantic similarity between three Gene Ontology slims (Plant, Yeast, and Candida, among which the latter two belong to the same kingdom—Fungi) using four popular measures commonly applied to biomedical ontologies (Resnik, Lin, Jiang-Conrath, and SimRel). The results of this study demonstrate that with proper selection of scaling levels and similarity measures, we can significantly reduce the size of ontologies without losing substantial detail. In particular, the performance of Jiang-Conrath and Lin are more reliable and stable than that of the other two in this experiment, as proven by (a) consistently showing that Yeast and Candida are more similar (as compared to Plant) at different scales, and (b) small deviations of the similarity values after excluding a majority of nodes from several lower scales. This study provides a deeper understanding of the application of semantic similarity to biomedical ontologies, and shed light on how to choose appropriate semantic similarity measures for biomedical engineering.
Abstract Objective We describe a detailed solution for maintaining high-capacity, data-intensive network flows (eg, 10, 40, 100 Gbps+) in a scientific, medical context while still adhering to security and privacy laws and regulations. Materials and Methods High-end networking, packet-filter firewalls, network intrusion-detection systems. Results We describe a “Medical Science DMZ” concept as an option for secure, high-volume transport of large, sensitive datasets between research institutions over national research networks, and give 3 detailed descriptions of implemented Medical Science DMZs. Discussion The exponentially increasing amounts of “omics” data, high-quality imaging, and other rapidly growing clinical datasets have resulted in the rise of biomedical research “Big Data.” The storage, analysis, and network resources required to process these data and integrate them into patient diagnoses and treatments have grown to scales that strain the capabilities of academic health centers. Some data are not generated locally and cannot be sustained locally, and shared data repositories such as those provided by the National Library of Medicine, the National Cancer Institute, and international partners such as the European Bioinformatics Institute are rapidly growing. The ability to store and compute using these data must therefore be addressed by a combination of local, national, and industry resources that exchange large datasets. Maintaining data-intensive flows that comply with the Health Insurance Portability and Accountability Act (HIPAA) and other regulations presents a new challenge for biomedical research. We describe a strategy that marries performance and security by borrowing from and redefining the concept of a Science DMZ, a framework that is used in physical sciences and engineering research to manage high-capacity data flows. Conclusion By implementing a Medical Science DMZ architecture, biomedical researchers can leverage the scale provided by high-performance computer and cloud storage facilities and national high-speed research networks while preserving privacy and meeting regulatory requirements.
Biomedical ontologies are key elements for building up the Life Sciences Semantic Web. Reusing and building biomedical ontologies requires flexible and versatile tools to manipulate them efficiently, in particular for enriching their axiomatic content. The Ontology Pre Processor Language (OPPL) is an OWL-based language for automating the changes to be performed in an ontology. OPPL augments the ontologists’ toolbox by providing a more efficient, and less error-prone, mechanism for enriching a biomedical ontology than that obtained by a manual treatment. We present OPPL-Galaxy, a wrapper for using OPPL within Galaxy. The functionality delivered by OPPL (i.e. automated ontology manipulation) can be combined with the tools and workflows devised within the Galaxy framework, resulting in an enhancement of OPPL. Use cases are provided in order to demonstrate OPPL-Galaxy’s capability for enriching, modifying and querying biomedical ontologies. Coupling OPPL-Galaxy with other bioinformatics tools of the Galaxy framework results in a system that is more than the sum of its parts. OPPL-Galaxy opens a new dimension of analyses and exploitation of biomedical ontologies, including automated reasoning, paving the way towards advanced biological data analyses.
In this study, the microstructures and mechanical properties of Ti-10Mo and Ti-20Mo alloys (mass%) are investigated to assess the potential use in biomedical applications. The microstructures are examined by X-ray diffraction analysis (XRD) and scanning electron microscopy (SEM). The mechanical properties are determined from uniaxial tensile tests. The experimental results indicate that the microstructures and mechanical properties of Ti-Mo alloys are dependent upon the cold rolling, solution heat treatment, and Mo content. The Ti-10Mo alloy exhibits ({alpha}'' + {beta}) and ({beta} + {omega}) phases under the cold rolling (CR) and solution treatment (ST), respectively. By contrast, the Ti-20Mo alloy comprises only {beta} phase under such conditions. The quenched Ti-20Mo alloy has the lowest elastic modulus and CR Ti-20Mo alloy has the highest tensile strength. The quenched Ti-10Mo alloy exhibits the excellent ductility and two-stage yielding from stress-strain curves due to the stress-induced martensite transformation from {beta} to {alpha}'' during tensile deformation. These Ti-Mo alloys exhibit low yield strength and good ductility, and they are more suitable for biomedical applications than the conventional metallic biomaterials from the viewpoint of better mechanical compatibility. The quenched Ti-10Mo alloy has some advantages over the other {beta} binary Ti-Mo alloys for biomedical applications. {beta} type Ti-Mo-Sn alloys are expected to be promising candidates for novel metallic biomaterials. - Highlights: {yields} The microstructures and mechanical properties of Ti-Mo alloys are dependent upon the cold rolling, solution heat treatment, and Mo content. {yields} The quenched Ti-10Mo alloy exhibits the excellent ductility and two-stage yielding due to stress-induced martensite transformation from beta to alpha double prime during tensile deformation. {yields} The Ti-Mo alloys are more suitable for biomedical applications than the conventional metallic biomaterials from the viewpoint of better mechanical compatibility. {yields} The quenched Ti-10Mo alloy has more advantages over the other beta binary Ti-Mo alloys for biomedical applications.
The National User Resource for Biological Accelerator Mass Spectrometry (User Resource) will provide isotopic analysis (primarily radiocarbon or 14C) by accelerator mass spectrometry (AMS) for NIH- funded researchers across the United States and will be the only User Resource of its type in the United States. The User Resource will provide measurement capability and expertise to a research community that requires highly sensitive, quantitative isotope analyses. Since commissioning a new accelerator mass spectrometer in June 2014, we have measured over 4000 samples a year for collaborators and service users. The User Resource will enable us to continue to meet these research needs, as well as provide for new users whose research programs would benefit from AMS as a measurement tool. The User Resource’s forte will be ultra-high sensitivity quantitation of radiocarbon and selected other radioisotopes for research studies where isotopes are required. Radioisotope labeling studies have been and will continue to be an important tool for addressing many complex biomedical science problems. AMS is a specialized and unique type of mass spectrometry that provides absolute quantitation of radiocarbon and other relevant radioisotopes with extreme sensitivity, having limits of detection in real samples on the order of a few attomol/mg of sample at measurement precisions of ~3%. It is the only instrumental method capable of quantifying radioisotope-labeled agents routinely in real-world samples with such precision and sensitivity. The sensitivity of AMS allows for the quantification of radiolabeled metabolites in extremely complex matrices of cells and organisms at very low concentrations and in small samples. AMS allows studies to be conducted without perturbing metabolism leading to more relevant quantification of metabolic rates and pathways. In addition, it enables quantification of pharmacokinetic and metabolic properties of toxicants at environmentally relevant concentrations in model systems as well as the ability to quantify pharmacokinetics and other molecular endpoints directly in humans. Such quantitative assessments can 1) improve risk assessment for toxicants, 2) address safety and efficacy considerations for therapeutic entities, 3) deepen understanding of xenobiotic and intermediary metabolism, 4) help understand the interactions between critical molecular pathways, and 5) improve efforts to model and predict various metabolic and biological states. These capabilities have been applied in a number of areas including research in carcinogenesis, toxicology, nutrition, pharmacology/drug development and basic biological science. As a NIGMS National Resource the National User Resource for Biological Accelerator Mass Spectrometry will help NIH funded scientists achieve a deeper understanding of the etiology of human health concerns by (1) enabling the quantification of pharmacokinetics and other molecular endpoints directly in humans; (2) offering the ability to conduct quantitative studies using biologics such as proteins or lipids, and thereby reducing the amount of radioisotope usage in biomedical labs; and (3) enabling more relevant studies of metabolic pathways in health and disease through the use of much lower, more biologically-relevant, concentrations of metabolic substrates in cells and intact organisms. Such studies support NIGMS’s basic biomedical research areas that contribute to the understanding of fundamental cellular and physiological principles and enable research supported by the Biophysics, Biomedical Technology, and Computational Biosciences (BBCB); Genetics and Molecular, Cellular, and Developmental Biology (GMCDB); Pharmacology, Physiology, Biological Chemistry (PPBC) and Training, Workforce Development, and Diversity (TWD) Divisions. Over the next five years, our goals are to: 1. Improve the efficiency of operation for AMS measurements through installation of new interfaces to our AMS systems, technical modifications to improve gas accepting ion source efficiency and upgrading our data analysis software for improved ease of use and data reporting. 2. Increase the accessibility and visibility of ultra-sensitive 14C measurements for the biomedical research community by training of new investigators and expanding our national user base. 3. Provide high throughput, ultra-sensitive 14C analysis for the NIGMS and NIH user community.
The design of space-station configurations is influenced by many factors, Probably the most demanding and critical are the biomedical and external hazards requirements imposed to provide the proper environment and supporting facilities for the crew and the adequate protective measures necessary to provide a configuration in which the crew can live and work efficiently in relative comfort and safety. The major biomedical factors, such as physiology, psychology, nutrition, personal hygiene, waste management, and recreation, all impose their own peculiar requirements. The commonality and integration of these requirements demand the utmost ingenuity and inventiveness be exercised in order to achieve effective configuration compliance. The relationship of biomedical factors for the internal space-station environment will be explored with respect to internal atmospheric constituency, atmospheric pressure levels, oxygen positive pressure, temperature, humidity, CO2 concentration, and atmospheric contamination. The range of these various parameters and the recommended levels for design use will be analyzed. Requirements and criteria for specific problem areas such as zero and artificial gravity and crew private quarters will be reviewed and the impact on the design of representative solutions will be presented. In the areas of external hazards, the impact of factors such as meteoroids, radiation, vacuum, temperature extremes, and cycling on station design will be evaluated. Considerations with respect to operational effectiveness and crew safety will be discussed. The impact of such factors on spacecraft design to achieve acceptable launch and reentry g levels, crew rotation intervals, etc., will be reviewed. Examples of configurations, subsystems, and internal a arrangement and installations to comply with such biomedical factor requirements will ber presented. The effects of solutions to certain biomedical factors on configuration weight, operational convenience, and program costs will be compared.
The APBS software was developed to solve the equations of continuum electrostatics for large biomolecular assemblages. APBS has enjoyed widespread adoption throughout the biomedical community and is used in numerous applications involving biomolecular structures. However, visualization of complex biomolecular electrostatic properties can be challenging for two-dimensional graphics systems. Therefore, advanced visualization and manipulation capabilities have been incorporated. In particular, APBS tools have been integrated with the UnityMolX virtual reality platform to provide an immersive experience for preparing biomolecular systems for calculations as well as visualizing and comparing calculated results.
Highlights: • The heating rate, isothermal temperature and aging time strongly affect the phase precipitation. • Aged Ti35Nb alloy presented an ultimate tensile strength of 972 MPa with elongation of 7.5%. • The elastic modulus of 78 GPa makes this aged alloy a promising candidate for biomedical application. - Abstract: Metastable β Ti alloys based on Nb exhibit features that make them suitable for load-bearing biomedical applications, so it is crucial to evaluate their phase transformation and properties. This paper discusses the effects of aging heat treatments on the microstructure, phase transformation and mechanical behavior of Ti35Nb alloy. Samples were solution heat treated in the β field, quenched and aged under different conditions of heating rates, isothermal aging temperature and isothermal aging time. To enhance the alloy's mechanical behavior, thermal analysis and high temperature X-ray diffraction experiments coupled with Vickers hardness tests were employed to determine the temperature range of isothermal ω phase precipitation, as well as α phase precipitation temperature, thereby providing information to optimize aging heat treatment conditions. Results indicate that Ti35Nb alloy subjected to a heating rate of 30 °C/min and an isothermal aging temperature of 500 °C applied for 4 h would ensure high mechanical strength and low elastic modulus. The application of these aging conditions led to a microstructure consisting of very refined α phase precipitates homogeneously dispersed in the β phase matrix, presenting an ultimate tensile strength of 972 MPa, elongation of 7.5% and elastic modulus of 78 GPa, making this aged alloy a promising candidate for biomedical applications. These results shed light on the correlations between phase transformations, microstructure and mechanical behavior in high solute content TiNb alloys for biomedical applications.
The National User Resource for Biological Accelerator Mass Spectrometry (User Resource) will provide isotopic analysis (primarily radiocarbon or 14C) by accelerator mass spectrometry (AMS) for NIH- funded researchers across the United States and will be the only User Resource of its type in the United States. The User Resource will provide measurement capability and expertise to a research community that requires highly sensitive, quantitative isotope analyses. Since commissioning a new accelerator mass spectrometer in June 2014, we have measured over 4000 samples a year for collaborators and service users. The User Resource will enable us to continue to meet these research needs, as well as provide for new users whose research programs would benefit from AMS as a measurement tool. The User Resource’s forte will be ultra-high sensitivity quantitation of radiocarbon and selected other radioisotopes for research studies where isotopes are required. Radioisotope labeling studies have been and will continue to be an important tool for addressing many complex biomedical science problems. AMS is a specialized and unique type of mass spectrometry that provides absolute quantitation of radiocarbon and other relevant radioisotopes with extreme sensitivity, having limits of detection in real samples on the order of a few attomol/mg of sample at measurement precisions of ~3%. It is the only instrumental method capable of quantifying radioisotope-labeled agents routinely in real-world samples with such precision and sensitivity. The sensitivity of AMS allows for the quantification of radiolabeled metabolites in extremely complex matrices of cells and organisms at very low concentrations and in small samples. AMS allows studies to be conducted without perturbing metabolism leading to more relevant quantification of metabolic rates and pathways. In addition, it enables quantification of pharmacokinetic and metabolic properties of toxicants at environmentally relevant concentrations in model systems as well as the ability to quantify pharmacokinetics and other molecular endpoints directly in humans. Such quantitative assessments can 1) improve risk assessment for toxicants, 2) address safety and efficacy considerations for therapeutic entities, 3) deepen understanding of xenobiotic and intermediary metabolism, 4) help understand the interactions between critical molecular pathways, and 5) improve efforts to model and predict various metabolic and biological states. These capabilities have been applied in a number of areas including research in carcinogenesis, toxicology, nutrition, pharmacology/drug development and basic biological science. As a NIGMS National Resource the National User Resource for Biological Accelerator Mass Spectrometry will help NIH funded scientists achieve a deeper understanding of the etiology of human health concerns by (1) enabling the quantification of pharmacokinetics and other molecular endpoints directly in humans; (2) offering the ability to conduct quantitative studies using biologics such as proteins or lipids, and thereby reducing the amount of radioisotope usage in biomedical labs; and (3) enabling more relevant studies of metabolic pathways in health and disease through the use of much lower, more biologically-relevant, concentrations of metabolic substrates in cells and intact organisms. Such studies support NIGMS’s basic biomedical research areas that contribute to the understanding of fundamental cellular and physiological principles and enable research supported by the Biophysics, Biomedical Technology, and Computational Biosciences (BBCB); Genetics and Molecular, Cellular, and Developmental Biology (GMCDB); Pharmacology, Physiology, Biological Chemistry (PPBC) and Training, Workforce Development, and Diversity (TWD) Divisions.